kisplyx
eisai gmbh - lenvatinibmesülaat - kartsinoom, neerurakk - antineoplastilised ained - kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (rcc):in combination with pembrolizumab, as first-line treatment (see section 5. in combination with everolimus, following one prior vascular endothelial growth factor (vegf)-targeted therapy.
amlodipine accord 5mg tablett
accord healthcare b.v. - amlodipiin - tablett - 5mg 10tk; 5mg 14tk; 5mg 20tk; 5mg 98tk; 5mg 90tk; 5mg 30tk; 5mg 1000tk; 5mg 100tk; 5mg 60tk; 5mg 250tk; 5mg 50tk
certican 0,75 mg tabletid tablett
novartis baltics sia - everoliimus - tablett - 0,75mg 250tk; 0,75mg 100tk; 0,75mg 60tk; 0,75mg 50tk
certican 1 mg tabletid tablett
novartis baltics sia - everoliimus - tablett - 1mg 60tk; 1mg 250tk; 1mg 50tk; 1mg 100tk
amlodipine accord 10mg tablett
accord healthcare b.v. - amlodipiin - tablett - 10mg 500tk; 10mg 10tk; 10mg 50tk; 10mg 90tk; 10mg 98tk; 10mg 100tk; 10mg 30tk; 10mg 250tk
dormicum õhukese polümeerikattega tablett
roche eesti osaühing - midasolaam - õhukese polümeerikattega tablett - 7,5mg 10tk
certican 0,25 mg tabletid tablett
novartis baltics sia - everoliimus - tablett - 0,25mg 50tk; 0,25mg 60tk; 0,25mg 250tk
certican 0,1 mg dispergeeruvad tabletid dispergeeruv tablett
novartis baltics sia - everoliimus - dispergeeruv tablett - 0,1mg 100tk; 0,1mg 60tk
certican 0,5 mg tabletid tablett
novartis baltics sia - everoliimus - tablett - 0,5mg 50tk; 0,5mg 100tk; 0,5mg 250tk; 0,5mg 60tk
certican 0,25 mg dispergeeruvad tabletid dispergeeruv tablett
novartis baltics sia - everoliimus - dispergeeruv tablett - 0,25mg 100tk; 0,25mg 60tk; 0,25mg 50tk; 0,25mg 250tk